Svar Life Science

July 19, 2022

Editorial Article: How biosimilars are expanding options for patient care

In this Editorial Article, Heather Watson, Senior Manager in the Immunochemistry Department at Labcorp highlights how the industry is improving patient care by delivering innovative solutions that support faster and more cost-effective treatment.

 

The article also deals with the regulatory challenges in biosimilar development and how to address those challenges through in-house efforts or by partnering with other organizations offering specialized services and products in this area, such as Labcorp and Svar Life Science.

July 19, 2022

Editorial Article: How biosimilars are expanding options for patient care

In this Editorial Article, Heather Watson, Senior Manager in the Immunochemistry Department at Labcorp highlights how the industry is improving patient care by delivering innovative solutions that support faster and more cost-effective treatment.

 

The article also deals with the regulatory challenges in biosimilar development and how to address those challenges through in-house efforts or by partnering with other organizations offering specialized services and products in this area, such as Labcorp and Svar Life Science.

BIOSIMILAR DEVELOPMENT 
Giving rise to a unique set of challenges

To reach the market, biosimilars must follow a strict regulatory pathway and meet stringent requirements set by different regulatory agencies across the globe, which gives rise to a unique set of challenges.

Scientists at biotherapeutic companies can choose to address these challenges through in-house efforts, or partner with other organizations offering specialized services and products in this area, such as Labcorp and Svar Life Science. 


Complete the form to access the editorial article!

OUR SOLUTIONS FOR BIOSIMILAR DEVELOPMENT

Bioanalytical Services

We offer bioanalytical services for biosimilar development to help overcome several of the common challenges, such as bioanalytical program design, analyzing the clinical significance of identified differences, and obtaining critical reagents.

We can also help put processes in place for PK and immunogenicity biosimilar assay design, and validation aspects, along with biosimilar bioanalytical development and sample analysis.  > Learn more

Functional mechanism of action (MoA)-reflective products

The iLite® cell-based reporter-gene assays are MOA-reflective and biologically relevant assays that offer a fast and convenient way to measure and quantify drug activity and immunogenicity accurately.

As an added benefit, the cells are provided assay-ready for a quicker workflow and contain a second normalization reporter-gene for added convenience. > Learn more